Gastrointestinal side effects are the main reason people stop treatment. Typical issues include nausea, vomiting, constipation and diarrhoea. The review explicitly discusses the impact of side effects ...

Please provide your email address to receive an email when new articles are posted on . No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs ...

Adults with differentiated thyroid cancer who are using a GLP-1 for the treatment of diabetes or obesity do not have increased risk for cancer recurrence or progression vs. those not using a GLP-1, ...

A new white paper issued by the Clayman Thyroid Center in Tampa, Florida, concludes that popular GLP-1 receptor agonists ...

A Clayman Thyroid Center report aims to clarify FDA safety warnings, finding no evidence that GLP-1 drugs like Ozempic cause common thyroid cancers. Current human data do not show a link between GLP-1 ...

No significant association was found between the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thyroid cancer over nearly 4 years. A cohort study using data from nationwide ...

A Scandinavian cohort study suggested a popular class of diabetes drug did not put patients at an elevated risk for thyroid cancer, a longtime lingering concern with this drug class. Compared with DPP ...

Glucagon-like peptide-1 receptor agonist therapy with liraglutide or semaglutide is not associated with an increased risk for thyroid cancer among patients with type 2 diabetes or obesity, according ...

When prescription depression drugs fall short in efficacy, there’s an off-label way to help them work better: add-on doses of thyroid hormone. Clinicians have long known about this approach and some ...

Tris (1,3-dichloropropyl) phosphate (TDCPP) is a high-production-volume organophosphate ester flame retardant, with maximum concentrations of several tens of micrograms per liter (μg/L) in ambient ...